Page 1

Exhibit 99.1 Perrigo FOR RELEASE Perrigo to Acquire Leading Consumer Self - Care Company , HRA Pharma • • Transaction would complete Perrigo's three - year transformation plan to become a global leader in consumer self - care ; positions Perrigo to deliver top - tier net sales growth and double - digit EPS growth , with significant margin expansion . Would add HRA's focused portfolio of market leading , high growth OTC self - care brands in blister care , women's health and scar care to Perrigo's expert direct go - to - market platform . Acquisition of HRA for € 1.8 billion , or approximately $ 2.1 billion ( 1 ) , in cash would represent an enterprise value to expected 2022 adjusted EBITDA multiple of 18x . Adding anticipated synergies expected by 2023 on a pro forma basis , purchase price would represent an adjusted EBITDA multiple of less than 14x . Would significantly strengthen Perrigo's global footprint by adding scale in key European markets . Overlap with existing geographies expected to provide significant and actionable operational synergies . Transaction is anticipated to accelerate results for both Consumer Self - Care segments and be immediately accretive to Perrigo , adding approximately € 400 million in net sales and approximately $ 1.00 in adjusted EPS in FY 2023 . HRA's seasoned leadership team will remain in place to minimize any business disruption from integration . Conference call and webcast scheduled for today , September 8 , 2021 , at 8:30 A.M. EDT to discuss transaction . ( 1 ) Assumes euro / dollar exchange rate of € 1.00 / $ 1.19 as of September 7 , 2021 . Dublin , Ireland - September 8 , 2021 - Perrigo Company plc ( NYSE , TASE : PRGO ) ( “ Perrigo " or the " Company " ) today announced that it has signed a binding offer to acquire Héra SAS ( " HRA ” or “ HRA Pharma " ) , a leading global consumer self - care company , from funds affiliated with private equity firm Astorg and Goldman Sachs Asset Management . The transaction is valued at € 1.8 billion , or approximately $ 2.1 billion in cash . HRA is one of the fastest growing over - the - counter ( " OTC " ) companies globally , with three category - leading self - care brands in blister care ( Compeed® ) , women's health ( ellaOne® ) and scar care ( Mederma® ) . This scale acquisition would complete Perrigo's transformation to a global leader in consumer self - care , bolster its presence in high - potential European markets and meaningfully improve its already strong operational and financial profile . 1